NikoleV Posted June 13 Share Posted June 13 What an exciting past month it has been for small cell lung cancer! Dr. Misty Shields provided the wonderful update below. Tell us..... With all the new treatment options for SCLC, what are you most hopeful for? Small Cell SMASHERS: We had our first Facebook live announcing the partnership between Small Cell SMASHERS and LUNGevity Foundation. You can view the recording here: https://www.facebook.com/share/v/GimdUTgYTgsUvoit/ More updates including monthly interviews coming soon! Relapsed/Refractory Extensive-Stage SCLC: On May 16, 2024, the U.S. Food & Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra) for patients with ES-SCLC with disease progression on/after platinum-based chemotherapy. On June 11, 2024, the National Comprehensive Cancer Network (NCCN) released updated treatment guidelines for SCLC. Limited-Stage SCLC: On June 2, 2024, the ADRIATIC investigators presented Phase III data from consolidation durvalumab for 2 years from chemoradiation with an impressive 22 month improvement in median overall survival. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.